invios-Logo-RGB-small.jpg
invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding
September 05, 2023 03:00 ET | invIOs GmbH
Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started;invIOs awarded up to...
invios-Logo-RGB-small.jpg
invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023
April 18, 2023 09:00 ET | invIOs GmbH
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver...
invios-Logo-RGB-small.jpg
invIOs to present at Biotech Showcase
December 14, 2022 08:00 ET | invIOs GmbH
VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter...
invios-Logo-RGB-small.jpg
invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022
November 10, 2022 09:40 ET | invIOs GmbH
Poster presentation shows treatment with APN401, an autologous cell therapy product targeting the master immune checkpoint Cbl-b, resulted in stabilization of disease for more than six months in a...
invios-Logo-CMYK-300DPI.jpg
invIOs to present data from clinical stage Cbl-b program at SITC 2022
October 18, 2022 02:00 ET | invIOs GmbH
VIENNA, Austria, Oct. 18, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its...
invios-Logo-CMYK-300DPI.jpg
invIOs to present at upcoming industry and investor conferences
October 11, 2022 02:00 ET | invIOs GmbH
VIENNA, Austria, Oct. 11, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces its participation at three...
invios-Logo-CMYK-300DPI.jpg
APEIRON shareholders approve new group structure geared towards enabling innovation and growth
April 26, 2022 02:00 ET | invIOs GmbH
VIENNA, Austria, April 26, 2022 (GLOBE NEWSWIRE) -- APEIRON Biologics AG announces that the annual general meeting held yesterday has approved the new structure of the group through the demerger of...
invios-Logo-CMYK-300DPI.jpg
invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline
December 16, 2021 02:00 ET | invIOs GmbH
VIENNA, Austria, Dec. 16, 2021 (GLOBE NEWSWIRE) -- invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for cancer, is pleased to announce it...